Last reviewed · How we verify
NCT06077292: THC-YA
Cannabis THC Potency, Metabolism, and Cognitive Impairment in Young Adults
NA trial testing 15% THC Potency Reduction in Cannabis Use in 110 participants. Suspended.
14 March 2026
Quick facts
| Lead sponsor | University of California, San Francisco |
|---|---|
| Phase | NA |
| Status | Suspended |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | other |
| Enrollment | 110 |
| Start date | 17 March 2025 |
| Primary completion | 14 March 2026 |
| Estimated completion | 14 December 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- 15% THC Potency Reduction
- 35% THC Potency Reduction
Conditions studied
- Cannabis Use — all drugs for Cannabis Use →
- THC — all drugs for THC →
- Marijuana Use — all drugs for Marijuana Use →
- Cognitive Impairment — all drugs for Cognitive Impairment →
Sponsor
University of California, San Francisco
Who can join
Adults 21 to 25, any sex, with Cannabis Use or THC. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this interventional study is to determine the impact of high potency THC product use on cognitive function of young adults aged 21-25. The main question it aims to answer is: will cannabis users who switch to less potent THC products demonstrate improved cognitive function compared to baseline? Other questions this study aims to answer include: * Can researchers accurately assess THC consumption among frequent cannabis users? * Can researchers effectively incentivize cannabis users to use less potent THC products? * Do genetic variations in THC metabolism impact urinary THC excretion? * Do genetic variations in THC metabolism impact cognitive performance in cannabis users? * Are quantitative urinary THC values predictive of cognitive impairment? * How can researchers use research findings to inform harm reduction practices for people who use cannabis? Participants will submit blood and urine samples and be incentivized to use less potent THC products.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06077292
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cannabis Use
Currently open trials in the same condition.
- NCT07196462 — Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia · NA · recruiting
- NCT07168707 — Culturally Adapted EAET-H for Chronic Pain Patients Using Medical Cannabis in Israel - A Pilot Study · NA · recruiting
- NCT05999383 — Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration · Phase 2 · recruiting
- NCT06883162 — Cannabis-Tobacco Co-Use Treatment Study · Phase 3 · recruiting
- NCT06699251 — Effectiveness of Brief Intervention in Primary Care for Diverse Young People (Chat) · NA · recruiting
Other University of California, San Francisco trials
Trials by the same sponsor.
- NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
- NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
- NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
- NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
- NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06077292 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06077292.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing